Cytokinetics Inc. (Nasdaq: CYTK) will present results from a Phase IIb clinical trial of omecamtiv mecarbil during a Hot Line Late Breaking Trials Session at the European Society of Cardiology Congress 2013. Cytokinetics will also join the Russell Global Index on June 28, 2013. Shares of the biopharmaceutical leaped 43 cents to close at $1.89.
Cytokinetics To Present Results
June 18, 2013 at 17:31 PM EDT
